



Synthetic Communications

An International Journal for Rapid Communication of Synthetic Organic Chemistry


ISSN: 0039-7911 (Print) 1532-2432 (Online) Journal homepage: <http://www.tandfonline.com/loi/lcyc20>


Facile synthesis of highly functionalized novel pyrazolopyridones using oxoketene dithioacetal and their anti-HIV activity

Mahesh M. Savant, Kartik D. Ladva & Archana B. Pandit


To cite this article: Mahesh M. Savant, Kartik D. Ladva & Archana B. Pandit (2018) Facile synthesis of highly functionalized novel pyrazolopyridones using oxoketene dithioacetal and their anti-HIV activity, *Synthetic Communications*, 48:13, 1640-1648, DOI: [10.1080/00397911.2018.1458239](https://doi.org/10.1080/00397911.2018.1458239)

To link to this article: <https://doi.org/10.1080/00397911.2018.1458239>

 View supplementary material 

 Published online: 08 Jun 2018.

 Submit your article to this journal 

 View related articles 

 View Crossmark data 



Facile synthesis of highly functionalized novel pyrazolopyridones using oxoketene dithioacetal and their anti-HIV activity

Mahesh M. Savant^a, Kartik D. Ladva^b, and Archna B. Pandit^b

^aDepartment of Industrial Chemistry, Shree M. & N. Virani Science College, Rajkot, Gujarat, India; ^bDepartment of Chemistry, Shree M. & N. Virani Science College, Rajkot, Gujarat, India

ABSTRACT

A series of novel 3-amino-4,5-dihydro-6-methyl-4-oxo-*N*-aryl-1*H*-pyrazolo[4,3-*c*]pyridine-7-carboxamide have been synthesized starting from various oxoketene dithioacetals. The cyclocondensation reaction of 2-(bis(methylthio)methylene)-3-oxo-*N*-arylbutanamide **2a-w** with cyanoacetamide using NaO*i*Pr as base under reflux condition afforded novel highly functionalized pyridone **3a-w** derivatives. Further, [3 + 2] cyclocondensation reaction of pyridones with hydrazine in the presence of alcohol yielded pyrazolopyridones (23 nos) **4a-w** with excellent yields. All newly synthesized compounds were evaluated for *in vitro* anti-HIV activity using MTT method. Most of these compounds have showed moderate to potent activity against HIV-1 (III_B) and HIV-2 (ROD) strains with an IC₅₀ ranging from >18 IC₅₀ [μg/ml] to <100 IC₅₀ [μg/ml]. Among them, compounds **4j** and **4v** were identified as the most promising compound for both types of HIV strains. (IC₅₀ = 18 μg/ml). Three compounds **4l**, **4m**, and **4p** have been found potent anti-HIV 1 and 2 activity against MT-4 cells.


ARTICLE HISTORY

Received 29 November 2017

KEYWORDS

Anti-HIV activity; highly functionalized pyrazolopyridone; ketene dithioacetals; MTT method


GRAPHICAL ABSTRACT



Introduction

The human immunodeficiency virus (HIV)—the etiologic agent of acquired immunodeficiency syndrome (AIDS)—is the fastest growing cause of death in women of reproductive age.^[1] The current therapy against the HIV type 1 (HIV-1), which is the etiological agent of AIDS, is based on six of categorized drugs: nucleoside/nucleotide reverse transcriptase

CONTACT Mahesh M. Savant  maheshsavant84@gmail.com  Department of Industrial Chemistry, Shree M. & N. Virani Science College, Rajkot-36005, Gujarat, India.

 Supplemental data for this article can be accessed on the [publisher's website](#).

© 2018 Taylor & Francis

inhibitors (NRTIs/NtRTIs); nonnucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs); cell entry inhibitors [fusion inhibitors (FIs); coreceptor inhibitors (CRIs)]; and integrase inhibitors (INIs).^[2] In 2003, NNRTIs like lersiverine, bearing pyrazole moiety, have received great attention in the field of anti-HIV research.^[3] Up to now, several polyazaaromatics have been studied and developed as NNRTI, including pyridones and pyrazoles.^[4-6]

Condensed polyazaaromatics have attracted significant attention from the scientific community because of their relevance in medicinal chemistry. Polyazaaromatics frequently can be observed in numerous bioactive small molecules, and in particular, fused with various heterocycles, such as pyrazole, pyridine, and pyrimidine, have been used as key pharmacophores.^[7] As shown in Figure 1, a blockbuster drug, sildenafil citrate (**1**),^[8] and a potent anticancer agent (**2**)^[9] contain polyazaaromatics fused with privileged heterocycles as core skeletons. In addition, 1*H*-pyrazolo[3,4-*b*]pyridine **3** is recognized as a privileged substructure, inhibitors were discovered by optimizing a fragment screening hit scaffold using structure guided design. These inhibitors show potent Gram-positive antibacterial activity and low resistance incidence against clinically important pathogens.^[10] Structure-based design of novel inhibitors that interact with the K103 backbone of HIV-reverse transcriptase has led to the discovery of NNRTIs that contain an unusual 1*H*-pyrazolo[3,4-*c*]pyridazine heterocycles (**4**).^[11] Recently, pyrazolopyridone **5** found as a novel class of noncovalent DprE1 inhibitor with potent antimycobacterial activity.^[12] Moreover, novel 2-pyridone derivatives **6** have been synthesized and found potent anti-HIV-1 (III_B) at low micromolar concentrations (EC₅₀ = 0.15–0.84 μM), comparable to that of Nevirapine and Delavirdine.^[13] These examples emphasize the importance




Figure 1. Biologically active pyrazolopyridones.

of pyridone, pyrazolopyridone as well as pyrazolopyridines, as key pharmacophores in bioactive small molecules. Several diverse biological activities have been reported for condensed pyrazolopyridone ring systems such as MAP kinase,^[14] antimicrobial,^[15] anti-Leishmania,^[16] PDE inhibitors,^[17] anti-HIV,^[18] anticancer.^[19] Literature survey reveals the significance of highly substituted pyrazolopyridone in medicinal chemistry. Herein, we report an efficient and easy synthesis of novel compounds based on the pyrazolopyridone backbone scaffold bearing a carboxamide side chain using various oxoketene dithioacetals for biological interest.

Fused pyrazolopyridone ring systems are present in a variety of biologically active compounds (both naturally occurring and synthetic). Although a large number of methods for their synthesis have been documented in the literature, many of them require multistep procedures using intermediates which are not readily available.^[20–34]

Results and discussion

In our efforts to discover novel anti-HIV agents^[2] and synthesis of various heterocyclic compounds using oxoketene dithioacetals,^[35–36] we have observed that oxoketene dithioacetals are versatile intermediate for the synthesis of pyrazolopyridone derivatives. All the synthesized compounds were screened for their *in vitro* anti-HIV activity against human HIV cell line. These compounds were required to achieve 50% protection of MT-4 cells from the HIV-1-induced cytopathogenicity, as determined by the MTT method.


Initially, the reaction of 2-(bis(methylthio)methylene)-3-oxo-*N*-phenylbutanamide (**2a**) with cyanoacetamide (CA) was performed using sodium methoxide in methanol. The reaction of **2a** with CA in sodium methoxide was afforded the product **3a** in 75% yield with long reaction time (Table 1). To optimize the reaction condition for the synthesis of compound **3a**, various sodium alkoxides were utilized in respective alcohol. As a result, we found the reaction of **2a** with CA was faster and afforded the pyridone **3a** in good yield in the presence of sodium isopropoxide and isopropyl alcohol. Various oxoketene dithioacetals **2a–w** have been prepared by our reported method.^[36] Moreover, the cyclocondensation reaction of pyridones with 4-methylbenzenesulfonylhydrazide was not promising to yield pyridones. We have observed that separation of pyridones salt was required to furnish the product in high yield. The one postreaction of oxoketene dithioacetals, cyanoacetamide, and hydrazine hydrate was not clean and yielded the desired product.

The resulting pyridones **3a–w** was further reacted with hydrazine hydrate in isopropyl alcohol under reflux condition to afford the desired pyrazolopyridone derivatives in excellent yield with short reaction time (Scheme 1). The synthesized compounds were confirmed by IR, Mass, ¹H, and ¹³C NMR spectroscopy and elemental analysis. All the synthesized compounds were evaluated for their *in vitro* antiviral activity using HIV-1 (III_B) and HIV-2 (ROD) strains

In mechanism, the cyanoacetamide on the treatment with base generates an anion at active methylene group which attacks on β -carbon of oxoketene dithioacetal. The amine

Table 1. Optimization reaction of **2a** with cyanoacetamide using various bases.

Entry	Base	Time h	Yield %
1	NaOMe	7	75
2	NaOEt	6	82
3	NaO ⁱ Pr	4	88



Scheme 1. Synthesis of highly functionalized pyrazolopyridone **4a-w** starting from oxoketene dithioacetals **2a-w**. Reagents and conditions: (a) i: K_2CO_3 , CS_2 , DMF, 0-5 oC to rt 2 hr, ii: MeI, DMF, 0-5 oC to rt overnight (b) CA, NaOiPr, iPA, rt to reflux, 4 hr (c) NH_2NH_2 , iPA, Reflux.

nucleophile attacks on carbonyl carbon and forms sodium salt of pyridine moiety by removal of methylthio and water molecule. The sodium salt on acidification afforded pyridone. The binucleophile hydrazine hydrate on reaction with pyridone forms pyrazolopyridone (Scheme 2).

In vitro anti-HIV assay of pyrazolopyridones


Three groups of the compounds were studied for anti-HIV activities according to the IC_{50} values measured on the wildtype HIV-1 & two cell lines: strong anti-HIV effect $0 < \text{IC}_{50} < 20 \mu\text{g/ml}$ (two compounds: **4j** and **4v**), moderate anti-HIV effect $20 < \text{IC}_{50} < 50 \mu\text{g/ml}$ (compounds **4l**, **4m**, and **4p** Table 2), and no antiproliferative effect, where $\text{IC}_{50} > 50 \mu\text{g/ml}$ was found (Table 2). The lowest IC_{50} value for HIV-1 and HIV-2 strain was found < 19.4 and $< 18.4 \mu\text{g/ml}$, respectively (**4j**), while some compounds were ineffective even at the applied $100 \mu\text{g/ml}$ concentration (i.e., **4b**, **4e**, **4h**, and **4t**)

Structure-activity reveals that electronegative substitution increases the potency, thus chloro and fluoro groups (**4j**, **4l**) play a vital role. Also, methyl substitution at *ortho* and *meta* positions (**4v**) shows moderate biological potential. Bulky substitution at phenyl group does not favorable and this explains the inactivity of compounds having nitro in **4i**, **4t**, and **4w** and methoxy in **4e** and **4k** molecules.

Experimental

Materials and methods

Melting points were determined on an electrothermal apparatus using open capillaries and are uncorrected. Thin-layer chromatography was performed on 0.2-mm pre-coated plates of silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365 nm) or with iodine vapor. IR spectra were recorded on a Bruker alpha FTIR spectrophotometer



Scheme 2. Plausible reaction mechanism for the formation of pyrazolopyridone.

using DRS prob. ^1H and ^{13}C NMR spectra were recorded on a Bruker AVANCE II (400 MHz, 100 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal standard. Mass spectra were recorded using a direct inlet probe on an Agilent technology GCMS5977A mass spectrometer. All reagents were purchased from Fluka, Loba, and Rankem and used without further purification. Anti-HIV screening has been done using protocol reported in the literature.^[37]

General procedure for the synthesis of pyridones 3a–w

To a well stirred mixture of cyanoacetamide (10 mmol) and sodium isopropoxide (10 mmol) in isopropyl alcohol was added the solution of ketene dithioacetals **2a–w** (10 mmol) in isopropyl alcohol within 10–15 min. The resulting reaction mixture was further stirred at rt for 15 min and heated to reflux for 4 to 5 hr on water bath. The reaction was being monitored by TLC Hexane: EtOAc (7:3). After completion of the reaction, the solvent was evaporated under *vacuo* and the resulting solid was treated with dilute HCl solution. Thus, the obtained solid was filtered, washed with water, and dried at rt to afford analytically pure products. The solid products were used for next step without further purification.

General procedure for the synthesis of pyrazolopyridones 4a–w

The mixture of substituted pyridones **3a–w** (5 mmol) and hydrazine hydrate (10 mmol) in isopropyl alcohol was refluxed for appropriate time on water bath. After completion of the

Table 2. Physical and in vitro anti-HIV activity data of highly functionalized pyrazolopyridones **4a-w**.

Entry	R	Time min	Yield %	HIV-1 III _B		HIV-2 ROD	
				IC ₅₀ ^a	CC ₅₀ ^b	IC ₅₀ ^a	CC ₅₀ ^b
4a	Ph	50	96	94.70	≥94.70	94.70	≥94.70
4b	4-CH ₃	65	95	100.00	>100.00	100.00	>100.00
4c	4-OCH ₃	40	96	88.8	=88.8	73.8	=73.8
4d	4-F	45	97	89	=89	83.9	=83.9
4e	2-OCH ₃	55	88	100.00	>100.00	100.00	>100.00
4f	2-CH ₃	65	89	83.3	=83.3	96.1	=96.1
4g	4-Cl	60	91	92.6	=92.6	93.5	=93.5
4h	4-Et	45	93	98.00	>98.00	98.00	>98.00
4i	4-NO ₂	50	95	56.8	=56.8	71.5	=71.5
4j	3-Cl,4-F	60	85	19.4	=19.4	18.4	=18.4
4k	5-Cl, 2-OCH ₃	65	87	73.1	=73.1	54.8	=54.8
4l	2,5-diCl	70	88	49.1	=49.1	48.8	=48.8
4m	2,5-diCH ₃	60	89	45.6	=45.6	49.5	=49.5
4n	4-Cl, 2-CH ₃	70	83	68.6	=68.6	60.4	=60.4
4o	3,4-diF	75	92	99.03	99.03	97.1	=97.1
4p	2-Cl	75	84	48.7	=48.7	42.6	=42.6
4q	2-F	60	85	98.9	=98.9	82.9	=82.9
4r	4-Br	55	92	94.6	=94.6	108.20	108.20
4s	3,4-diCl	60	94	71.08	71.08	62.9	=62.9
4t	3-NO ₂	55	84	101.00	≥101.00	101.00	≥101.00
4u	3-CH ₃	65	88	67.2	=67.2	68.3	=68.3
4v	2,3-diCH ₃	65	89	19.8	=19.8	19	=19
4w	2-OCH ₃ , 4-NO ₂	70	91	86.7	=86.7	81.1	=81.1
AZT				7.6	7.6	7.8	7.8

^aThe IC₅₀ values are the concentrations of the compounds which inhibit tumor cell growth by 50%, ^bCompd. Concd. (μg/ml) required to reduce the viability of mock-infected MT-4 cells by 50%, as determined by the colorimetric MTT method.

reaction, solid product was appeared in the reaction. The reaction mixture was cooled to room temperature. The separated product was then filtered and washed with *i*PA and dried at room temperature to furnished analytically pure products.

Conclusion

In summary, we have described an efficient and easy synthesis of highly functionalized novel pyrazolopyridone derivatives in excellent yields. The reaction of various oxoketene dithioacetals with cyanoacetamide was afforded the pyridone derivatives with good yields in the presence of base. Synthesis of pyridone was examined using various bases and sodium isopropoxide was found as an efficient base. The pyridones were further reacted with hydrazine hydrate to furnish pyrazolopyridones. The significance of current method is excellent yields of novel pyrazolopyridones with short reaction time for biological interest. All compounds were screened against HIV-1 III_B and HIV-2 ROD strains. Among them, **4j** and **4v** compounds were found active against both HIV-1 and 2 cell having IC₅₀ ranging from <19.4, <19.8, and <18.4, <19 μg/ml, respectively. Anticancer screening of synthesized pyrazolopyridone derivatives is under investigation.

Funding

Authors are thankful for financial assistance given under UGC-MiRP, New Delhi, Sanction No.: 47-605/13(WRO); Dated: 20/05/2014 and Shree M. & N. Virani Science College, Rajkot for providing central instrumentation & laboratory facilities and Prof. Pannecouque Rega Institute for Medical Research, KU Leuven, Belgium for providing Anti-HIV analysis.

References

- [1] D'Cruz, O. J.; Uckun, F. M. Novel Derivatives of Phenethyl-5-Bromopyridylthiourea and Dihydroalkoxybenzyloxopyrimidine are Dual-Function Spermicides with Potent Anti-Human Immunodeficiency Virus Activity. *Biol. Reprod.* **1999**, *60*, 1419. DOI: [10.1095/biolreprod60.6.1419](https://doi.org/10.1095/biolreprod60.6.1419).
- [2] Bhavsar, D.; Trivedi, J.; Parekh, S.; Savant, M.; Thakrar, S.; Bavishi, A.; Radadiya, A.; Vala, H.; Lunagariya, J.; Parmar, M.; et al. Synthesis and In Vitro Anti-HIV Activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)Acetamide Derivatives using MTT Method. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3443. DOI: [10.1016/j.bmcl.2011.03.105](https://doi.org/10.1016/j.bmcl.2011.03.105).
- [3] Mowbray, C. E.; Burt, C.; Corbau, R.; Gayton, S.; Hawes, M.; Perros, M.; Tan, I.; Price, A. D.; Quinton, F. J.; Selby, M. D.; et al. Pyrazole NNRTIs 4: Selection of UK- 453,061 (Iersivirine) as a Development Candidate. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5857. DOI: [10.1016/j.bmcl.2009.08.080](https://doi.org/10.1016/j.bmcl.2009.08.080).
- [4] Vite Caritino, H.; Mendez-Lucio, O.; Reyes, H.; Cabrera, A.; Chavez, D.; Medina-Franco, J. L. Advances in the Development of Pyridinone Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors. *RSC Adv.* **2016**, *6*, 2119. DOI: [10.1002/chin.201611243](https://doi.org/10.1002/chin.201611243).
- [5] Mowbray, C. E.; Corbau, R.; Hawes, M.; Jones, L. H.; Mills, J. E.; Perros, M.; Selby, M. D.; Stupple, P. A.; Webster, R. Pyrazole NNRTIs 3: Optimisation of Physicochemical Properties. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5603. DOI: [10.1016/j.bmcl.2009.08.043](https://doi.org/10.1016/j.bmcl.2009.08.043).
- [6] Mowbray, C. E.; Burt, C.; Corbau, R.; Gayton, S.; Hawes, M.; Perros, M.; Tran, I.; Price, D. A.; Quinton, F. J.; Selby, M. D.; et al. Pyrazole NNRTIs 4: Selection of UK-453,061 (Iersivirine) as a Development Candidate. *Bioorg. Med. Chem. Lett.* **2009**, *20*, 5857. DOI: [10.1016/j.bmcl.2009.08.080](https://doi.org/10.1016/j.bmcl.2009.08.080).
- [7] PCT Int. Appl. Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases. Patent WO 2007076092 A2 20070705, **2007**.
- [8] Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Sildenafil (VIAGRATM), a Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1819. DOI: [10.1002/chin.199649268](https://doi.org/10.1002/chin.199649268).
- [9] Yu, K.; Toral, B. L.; Shi, C.; Zhang, W. G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; et al. Biochemical, Cellular, and In Vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. *Cancer Res.* **2009**, *69*, 6232. DOI: [10.1158/0008-5472.can-09-0299](https://doi.org/10.1158/0008-5472.can-09-0299).
- [10] Cross, J. B.; Zhang, J.; Yang, Q.; Mesleh, M. F.; Romero, J. A. C.; Wang, B.; Bevan, D.; Poutsiaka, K. M.; Epie, F.; Moy, T.; et al. Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design. *ACS Med. Chem. Lett.* **2016**, *7*(4), 374. DOI: [10.1021/acsmedchemlett.5b00368](https://doi.org/10.1021/acsmedchemlett.5b00368).
- [11] Sweeney, Z. K.; Harris, S. F.; Arora, N.; Javanbakht, H.; Li, Y.; Fretland, J.; Davidson, J. P.; Billedeau, R.; Gleason, S. K.; et al. Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase. *J. Med. Chem.* **2008**, *51*, 7449. DOI: [10.1021/jm800527x](https://doi.org/10.1021/jm800527x).
- [12] Panda, M.; Ramachandran, S.; Ramachandran, V.; Shirude, P. S.; Humnabadkar, V.; Nagalapur, K.; Sharma, S.; Kaur, P.; Guptha, S.; Narayan, A.; et al. Discovery of Pyrazolopyridones as a Novel Class of Noncovalent DprE1 Inhibitor with Potent Anti-Mycobacterial Activity. *J. Med. Chem.* **2014**, *57*(11), 4761. DOI: [10.1021/jm5002937](https://doi.org/10.1021/jm5002937).
- [13] Chen, W.; Han, Y.; Zhan, P.; Rai, D.; De Clercq, E.; Pannecouque, C.; Balzarini, J.; Zhou, Z.; Liu, H.; Liu, X.; et al. Discovery of 2-Pyridone Derivatives as Potent HIV-1 NNRTIs using Molecular Hybridization Based on Crystallographic Overlays. *Bioorg. Med. Chem.* **2014**, *22*, 1863. DOI: [10.1016/j.bmc.2014.01.054](https://doi.org/10.1016/j.bmc.2014.01.054).
- [14] Gabriel, T.; Yan, L. Pyrazolopyridine Derivatives and Their Use as Kinase Inhibitors. Patent WO2008/104473 A2, **2008**.
- [15] Bishnoi, A.; Singh, S.; Tiwari, A. K.; Srivastava, K.; Raghuvir, R.; Tripathi, C. M. Synthesis, Characterization and Biological Activity of New Cyclization Products of 3-(4-Substituted Benzylidene)-2H-pyrido[1,2-a]Pyrimidine 2,4-(3H)-Diones. *J. Chem. Sci.* **2013**, *125*, 305.

- [16] Mello, H. D.; Echevarria, A.; Bernardino, A. M.; Cavalheiro, M. C.; Leon, L. L. Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis. *J. Med. Chem.* **2004**, *47*, 5427. DOI: [10.1021/jm0401006](https://doi.org/10.1021/jm0401006).
- [17] Riccardo, G.; Clossek, D.; Christian, E.; Dennis, F. 1-Heterocyclyl-1,5-Dihydro-Pyrazolo[3,4-d]Pyrimidin-4-one Derivatives and Their use as pde9a Modulators. Patent WO 2009/121919, **2009**.
- [18] Zhan, P.; Li, D.; Chen, X.; Liu, X.; De Clercq, E. Functional Roles of Azoles Motif in Anti-HIV Agents. *Curr. Med. Chem.* **2011**, *18*, 29. DOI: [10.2174/092986711793979733](https://doi.org/10.2174/092986711793979733).
- [19] Christodoulou, M. S.; Fokialakis, N.; Nam, S.; Jove, R.; Skaltsounis, A. L.; Haroutounian, S. A. Synthesis and In Vitro Biological Evaluation of Novel Pyrazole Derivatives as Potential Antitumor. *Agents Med. Chem.* **2012**, *8*(5), 779. DOI: [10.2174/157340612802084252](https://doi.org/10.2174/157340612802084252).
- [20] Adamo, M. F. A.; Duffy, E. F.; Donati, D.; Fantoni, P. S. Modular Synthesis of Isoxazolepyridones and Pyrazolopyridones. *Tetrahedron* **2007**, *63*, 2047. DOI: [10.1016/j.tet.2006.12.044](https://doi.org/10.1016/j.tet.2006.12.044).
- [21] Jeyaveeran, J. C.; Praveen, C.; Arun, Y.; Prince, A. A. M.; Perumal, P. T. Cycloisomerization of Acetylenic Oximes and Hydrazones under Gold Catalysis: Synthesis and Cytotoxic Evaluation of Isoxazoles and Pyrazoles. *J. Chem. Sci.* **2016**, *128*, 73. DOI: [10.1007/s12039-015-0993-9](https://doi.org/10.1007/s12039-015-0993-9).
- [22] Kendall, J. D. Synthesis and Reactions of Pyrazolo[1,5-a]Pyridines and Related Heterocycles. *Curr. Org. Chem.* **2011**, *15*, 2481. DOI: [10.1002/chin.201148254](https://doi.org/10.1002/chin.201148254).
- [23] Kumar, A.; Ila, H.; Junjappa, H. Ketene Dithioacetals. Part 11. Reaction of 3-Cyano-4-Methylthio-2(1H)-Pyridones with hydrazine and Guanidine: Synthesis of Novel Substituted and Fused Pyrazolo[4,3-c]Pyridone and pyrido[4,3-d]Pyrimidine Derivatives. *J. Chem. Soc., Perkin Trans. 1* **1978**, *63*, 857.
- [24] Elgemeie, G. H.; Elghandour, A. H.; Elzanate, A. M.; Ahmed, S. A. Synthesis of Some Novel α -Cyanoketene S,S-Acetals and Their use in Heterocyclic Synthesis. *J. Chem. Soc., Perkin Trans. 1* **1977**, *21*, 3285. DOI: [10.1039/a702343j](https://doi.org/10.1039/a702343j).
- [25] Elgemeie, G. H.; Ali, H. A.; Elghandour, A. H.; Abdel-Aziz, H. M. A New General Method for Substituted 4-Alkylthio-n-Arylsulphonyl-Amino-2-Pyridones: Reaction of Ketene-ss-acetals with Arylsulphonylhydrazides. *Phosphorus, Sulfur Silicon Relat. Elem.* **2001**, *170*, 171. DOI: [10.1080/10426500108040593](https://doi.org/10.1080/10426500108040593).
- [26] Lacova, M.; Puchala, A.; Solcanyova, E.; Lac, J.; Kois, P.; Chovancova, J.; Rasala, D. 3-Formylchromones IV The Rearrangement of 3-Formylchromone Enamines as a Simple, Facile Route to Novel Pyrazolo[3,4-b]pyridines and the Synthetic Utility of the Latter. *Molecules* **2005**, *10*, 809. DOI: [10.3390/10070809](https://doi.org/10.3390/10070809).
- [27] Abass, M. Chemistry of Substituted Quinolinones. Part 8. Synthesis and Cyclization Reactions of Ethyl 5-Amino-1-(1-Methyl-2-Oxoquinolin-4-YL)-3-Methylsulfanylpazole-4-Carboxylate. *Phosphorus, Sulfur Silicon Relat. Elem.* **2003**, *178*, 1413. DOI: [10.1080/10426500307880](https://doi.org/10.1080/10426500307880).
- [28] Hassanein, A. E. B.. Synthesis and Reaction of Some Indenopyridine and Thieno[2,3-b]Indeno [2,1-e]Pyridine Derivatives. *Syn. Comm.* **2000**, *30*, 3883.
- [29] Lee, S.; Park, S. B.. An Efficient One-Step Synthesis of Heterobiaryl Pyrazolo[3,4-b]pyridines via Indole Ring Opening. *Org. Lett.* **2009**, *11*, 5214. DOI: [10.1021/ol902147u](https://doi.org/10.1021/ol902147u).
- [30] Joardar, S.; Roy, S.; Samanta, S.; Dutta, A. K.. Structure, Luminescence and Antimicrobial Properties of Mononuclear silver(I) Complexes of Pyridine 2-Carboxamide. *J. Chem. Sci.* **2015**, *127*, 1819. DOI: [10.1007/s12039-015-0947-2](https://doi.org/10.1007/s12039-015-0947-2).
- [31] Shi, D. Q.; Shi, J. W.; Yao, H.. Three-Component One-Pot Synthesis of Indeno[2',1':5,6]Pyrido [2,3-d]Pyrazole Derivatives in Aqueous Media. *J. Chin. Chem. Soc.* **2009**, *56*, 504. DOI: [10.1002/jccs.200900075](https://doi.org/10.1002/jccs.200900075).
- [32] Zhang, L. J.; Shi, D. X.; Li, J. R. Simultaneous Synthesis of Pyrazolopyridines and Pyrazolopyrimidinones Under Microwave Irradiation. *Syn. Comm.* **2009**, *39*, 4010. DOI: [10.1080/00397910902883629](https://doi.org/10.1080/00397910902883629).
- [33] Kaur, N.; Kishore, D. Application of Chalcones in Heterocycles Synthesis: Synthesis of 2-(Isoxazolo, Pyrazolo and Pyrimido) Substituted Analogues of 1,4-Benzodiazepin-5-Carboxamides Linked through an Oxyphenyl Bridge. *J. Chem. Sci.* **2013**, *125*, 555. DOI: [10.1002/jhet.1841](https://doi.org/10.1002/jhet.1841).

- [34] Ratajczyk, J. D.; Swett, L. R. The Cyclocondensation of 5-Amino-1,3-Dimethylpyrazole with Ethyl Acetoacetate. Synthesis of Isomeric Pyrazolopyridones. *J. Heterocycl. Chem.* **1975**, *12*, 517. DOI: [10.1002/chin.197541254](https://doi.org/10.1002/chin.197541254).
- [35] Savant, M. M.; Neetha, S. G.; Pansuriya, A. M.; Bhuva, C. V.; Kapuriya, N.; Anandalwar, S. M.; Prasad, S. J.; Shah, A.; Naliapara, Y. T. A Concise Synthetic Strategy to Functionalized Chromenones via [5+1] Heteroannulation and Facile C-N/C-S/C-O Bond Formation with Various Nucleophiles. *Tetrahedron Lett.* **2011**, *52*, 254. DOI: [10.1016/j.tetlet.2010.11.020](https://doi.org/10.1016/j.tetlet.2010.11.020).
- [36] Savant, M. M.; Pansuriya, A. M.; Bhuva, C. V.; Kapuriya, N.; Patel, A. S.; Audichya, V. B.; Pipaliya, P. V.; Naliapara, Y. T. Water Mediated Construction of Trisubstituted Pyrazoles/Isoxazoles Library Using Ketene Dithioacetals. *J. Comb. Chem.* **2010**, *12*, 176. DOI: [10.1002/chin.201023123](https://doi.org/10.1002/chin.201023123).
- [37] Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolium-Based Colorimetric Assay for the Detection of HIV Replication Inhibitors: Revisited 20 Years Later. *Nat. Protoc.* **2008**, *3*, 1. DOI: [10.1038/nprot.2007.517](https://doi.org/10.1038/nprot.2007.517).